Video

Ki-67 shows proven clinical utility as a predictive biomarker for breast cancer


 

Community Oncology Founding Editor Dr. Lee Schwartzberg, spoke with Dr. Joyce O'Shaughnessy at the Oncology Practice Summit in Las Vegas about emerging molecular biomarkers in breast cancer and shares some case-based treatment options to illustrate how these new predictive tools can be used.

The Oncology Practice Summit was the 8th annual meeting of Community Oncology, the journal of clinical issues in community practice. Dr. Schwartzberg was chair of the Summit, which was hosted this year by Community Oncology as well as The Journal of Supportive Oncology and The Oncology Report.

Recommended Reading

Lipid metabolism genes linked to breast cancer subtype
MDedge Hematology and Oncology
Breast cancer: Cardiac risk increases with radiation dose to heart
MDedge Hematology and Oncology
Contralateral prophylactic mastectomy adds complications
MDedge Hematology and Oncology
CancerLinQ prototype leverages 'Big Data'
MDedge Hematology and Oncology
Mammography screening at 75 may have value
MDedge Hematology and Oncology
What's in a name: Is the moniker 'palliative care' too loaded?
MDedge Hematology and Oncology
Dexamethasone eases end-of-life cancer-related fatigue
MDedge Hematology and Oncology
USPSTF draft recommendations update chemoprevention for breast cancer
MDedge Hematology and Oncology
Weight loss, exercise can impact cancer incidence and recurrence
MDedge Hematology and Oncology
Community Oncology Podcast: T-DM1 in HER-2 positive breast cancer
MDedge Hematology and Oncology